Variable | All patients | Tumor occupation ≥50% | Invasion with Vp4 | ||
---|---|---|---|---|---|
Yes | No | Yes | No | ||
Sample size | n = 84 | n = 31 | n = 53 | n = 30 | n = 54 |
Median age (range) | 53 (25–78) | 51 (29–78) | 53 (25–72) | 51 (29–78) | 53 (25–78) |
Sex | |||||
Male | 69 (82.1) | 25 (80.6) | 44 (83.0) | 25 (83.3) | 44 (81.5) |
Female | 15 (17.9) | 6 (19.4) | 9 (17.0) | 5 (16.7) | 10 (18.5) |
HBsAg | |||||
Positive | 71 (84.5) | 26 (83.9) | 45 (84.9) | 28 (93.3) | 43 (79.6) |
Negative | 13 (15.5) | 5 (16.1) | 8 (15.1) | 2 (6.7) | 11 (20.4) |
Child-Pugh class | |||||
A | 72 (85.7) | 23 (74.2) | 49 (92.5) | 25 (83.3) | 47 (87.0) |
B | 12 (14.3) | 8 (25.8) | 4 (7.5) | 5 (16.7) | 7 (13.0) |
BCLC stage | |||||
B | 15 (17.9) | 4 (12.9) | 11 (20.8) | 0 (0.0) | 15 (27.8) |
C | 69 (82.1) | 27 (87.1) | 42 (79.2) | 30 (100.0) | 39 (72.2) |
Extrahepatic metastasis | |||||
Yes | 42 (50.0) | 13 (41.9) | 29 (54.7) | 12 (40.0) | 30 (55.6) |
No | 42 (50.0) | 18 (58.1) | 24 (45.3) | 18 (60.0) | 24 (44.4) |
AFP level ≥ 400 μg/ml | |||||
Yes | 45 (53.6) | 20 (64.5) | 25 (47.2) | 19 (63.3) | 26 (48.1) |
No | 39 (46.4) | 11 (35.5) | 28 (52.8) | 11 (36.7) | 28 (51.9) |
Prior systemic treatment | |||||
Yes | 10 (11.9) | 5 (16.1) | 5 (9.4) | 0 (0.0) | 10 (18.5) |
No | 74 (88.1) | 26 (83.9) | 48 (90.6) | 30 (100.0) | 44 (81.5) |
Prior TACE | |||||
Yes | 33 (39.3) | 9 (29.0) | 24 (45.3) | 8 (26.7) | 25 (46.3) |
No | 51 (60.7) | 22 (71.0) | 29 (54.7) | 22 (73.3) | 29 (53.7) |
Maximum diameter of HCC ≥ 5 cm | |||||
Yes | 64 (76.2) | 30 (96.8) | 34 (64.2) | 27 (90.0) | 37 (68.5) |
No | 20 (23.8) | 1 (3.2) | 19 (35.8) | 3 (10.0) | 17 (31.5) |